{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:10Z","timestamp":1761870370386,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.03.028","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T01:02:17Z","timestamp":1307926937000},"page":"S96-S100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"11","author":[{"given":"Richard","family":"Champlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Anderlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borje","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.03.028_bib1","series-title":"Bone Marrow Transplantation","first-page":"595","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia","author":"Champlin","year":"1994"},{"key":"10.1016\/j.clml.2011.03.028_bib2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V60.4.1038.1038","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase","volume":"60","author":"Champlin","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib3","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood.V98.7.2039","article-title":"Chronic myeloid leukemia: current treatment options","volume":"98","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.028_bib5","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V95.7.2219","article-title":"Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program","volume":"95","author":"McGlave","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.V73.4.861.861","article-title":"Indications for marrow transplantation in chronic myelogenous leukemia","volume":"73","author":"Thomas","year":"1989","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2011.03.028_bib7","first-page":"S37","article-title":"BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices","volume":"6","author":"Kantarjian","year":"2008","journal-title":"J Natl Compr Canc Network"},{"key":"10.1016\/j.clml.2011.03.028_bib8","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.028_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.028_bib11","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Quintas-Cardama","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib13","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.028_bib14","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","article-title":"Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.028_bib15","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/ncponc0983","article-title":"Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?","volume":"5","author":"Hughes","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.clml.2011.03.028_bib18","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib19","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib20","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","article-title":"Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"107","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.028_bib23","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.028_bib24","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors","volume":"117","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.028_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history","volume":"24","author":"Jabbour","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.028_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.3429.3429","article-title":"Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure","author":"Jabbour","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib28","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib29","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib30","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib31","first-page":"28","article-title":"How does bone marrow transplantation cure leukemia?","volume":"2","author":"Gale","year":"1984","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2011.03.028_bib32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-2141.1996.d01-1713.x","article-title":"Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies","volume":"93","author":"Barrett","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.03.028_bib33","first-page":"18","article-title":"Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.03.028_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib35","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM198903303201303","article-title":"Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms","volume":"320","author":"Sullivan","year":"1989","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2011.03.028_bib36","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2011.03.028_bib38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib39","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib41","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus- leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib43","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.hoc.2004.03.009","article-title":"Nonmyeloablative stem cell transplantation for chronic myeloid leukemia","volume":"18","author":"Qazilbash","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2011.03.028_bib44","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.bbmt.2004.09.004","article-title":"Imatinib mesylate administration in the first 100 days after stem cell transplantation","volume":"10","author":"Anderlini","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2011.03.028_bib46","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib47","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib48","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2009.08.019","article-title":"Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)","volume":"16","author":"Klyuchnikov","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2011.03.028_bib50","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.028_bib51","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"suppl 3","key":"10.1016\/j.clml.2011.03.028_bib52","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.3816\/CLM.2009.s.021","article-title":"Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era","volume":"9","author":"Champlin","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2011.03.028_bib53","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.028_bib54","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib55","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.25092","article-title":"Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I","volume":"116","author":"Velev","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.03.028_bib56","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","article-title":"Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia","volume":"137","author":"Giralt","year":"2007","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2011.03.028_bib57","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/bmt.2008.105","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007","volume":"42","author":"Goldman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2011.03.028_bib58","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib59","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2010-01-263624","article-title":"Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase","volume":"115","author":"Pavlu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.028_bib60","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:26Z","timestamp":1761870146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":60,"alternative-id":["S2152265011000425"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.028","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}